Remove 2019 Remove Clinic Remove Individual Remove Relationship
article thumbnail

Long-Awaited Guidance on FDAMA 115: Confirmatory Evidence Finally Has Its Moment (to be Crossed Off the FDA’s Guidance To-Do List)

FDA Law Blog

The eagerly anticipated guidance, Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence (i.e., We are heartened to see that this latest guidance reflects many of the advances we observed in practice since 2019.

IT 64
article thumbnail

District Court Interprets EKRA

FDA Law Blog

In general, EKRA prohibits, knowingly and willfully, soliciting, receiving, paying or offering kickbacks in exchange for referring to, inducing a referral to, or using the services of a recovery home, clinical treatment facility, or laboratory. 18 U.S.C. § 18 U.S.C. § 220(e)(2). 18 U.S.C. § 24(b) (emphasis added). 18 U.S.C. § 220(b)(2). (C)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Change is Inevitable – Plan Ahead: An Assessment of FDA’s Draft Guidance on Predetermined Change Control Plans for Artificial Intelligence/Machine Learning-Enabled Device Software Functions

FDA Law Blog

In addition, manufacturers should identify whether the modifications will apply to all devices in the field (referred to as global adaptations) or will be implemented based on a specific clinical site or individual patients” (referred to as local adaptations).

article thumbnail

District Court Interprets EKRA

FDA Law Blog

In general, EKRA prohibits, knowingly and willfully, soliciting, receiving, paying or offering kickbacks in exchange for referring to, inducing a referral to, or using the services of a recovery home, clinical treatment facility, or laboratory. 18 U.S.C. § 18 U.S.C. § 220(e)(2). 18 U.S.C. § 24(b) (emphasis added). 18 U.S.C. § 220(b)(2). (C)

article thumbnail

Critics Suggest FDA Approving Aduhelm Will Erode the “Public Trust”: What About Patients’ Trust?

FDA Law Blog

I have witnessed it inform whether clinical trial results are clinically meaningful (or not) as well as the selection and even development of primary endpoints. What Dr. Cavazzoni lays out is the traditional way in which patients have informed drug benefit-risk decision-making: by setting the “clinical context” of the disease.

article thumbnail

Should you have a coach? Greg Pawlson, Beth Griffiths, & Vicky Tang

GeriPal

The initial RCT published on physician coaching in JAMA in 2019 showing that coaching improves quality of life. We’re doing a lot of interactive relationship building. Beth: Right now, I’m actually just doing individual coaching, but we are writing a grant to start group coaching next year. What does it mean to you?”

article thumbnail

Episode 213: Antiracism in Medicine Series – Episode 13 – Centering Asian Americans: Racism, Violence, and Health

The Clinical Problem Solvers

Appreciate how intergenerational trauma may surface amongst Asian-Americans, and how these intergenerational relationships may also offer fertile ground for generating understanding. Highlight how structural racism against Asian-Americans surfaces in clinical settings, and describe means of counteracting such structures.